Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab dosing algorithms in DME
NCT02366468Phase 4Completed
- Sponsor
- Novartis
- Start
- Feb 2015
- Primary completion
- Jun 2017
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ranibizumab in diabetic macular edema (DME), sponsored by Novartis. Started Feb 2015; status: completed.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02366468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02366468.